U.S. Biosimilar Contract Manufacturing Market Size & Outlook
U.S. biosimilar contract manufacturing market, 2018-2030 (US$M)
Related Markets
U.S. biosimilar contract manufacturing market highlights
- The U.S. biosimilar contract manufacturing market generated a revenue of USD 796.3 million in 2021 and is expected to reach USD 4,085.1 million by 2030.
- The U.S. market is expected to grow at a CAGR of 19.9% from 2022 to 2030.
- In terms of segment, recombinant non-glycosylated proteins was the largest revenue generating product in 2021.
- Recombinant Glycosylated Proteins is the most lucrative product segment registering the fastest growth during the forecast period.
Biosimilar contract manufacturing market data book summary
| Market revenue in 2021 | USD 796.3 million |
| Market revenue in 2030 | USD 4,085.1 million |
| Growth rate | 19.9% (CAGR from 2021 to 2030) |
| Largest segment | Recombinant non-glycosylated proteins |
| Fastest growing segment | Recombinant Glycosylated Proteins |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, IQVIA Holdings Inc, AGC Biologics, Samsung BioLogics, WuXi Biologics (Cayman) Inc, Rentschler Biopharma SE, Avid Bioservices Inc, FUJIFILM Holdings Corp, Thermo Fisher Scientific Inc, Biocon, Boehringer Ingelheim, Element Materials Technology, Alcami |
Other key industry trends
- In terms of revenue, U.S. accounted for 15.1% of the global biosimilar contract manufacturing market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. biosimilar contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 589.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimilar Contract Manufacturing Market Scope
Biosimilar Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. biosimilar contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilar contract manufacturing market will help companies and investors design strategic landscapes.
Recombinant non-glycosylated proteins was the largest segment with a revenue share of 55.18% in 2021. Horizon Databook has segmented the U.S. biosimilar contract manufacturing market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. biosimilar contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. biosimilar contract manufacturing market databook
-
Our clientele includes a mix of biosimilar contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. biosimilar contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. biosimilar contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. biosimilar contract manufacturing market size, by product, 2018-2030 (US$M)
U.S. Biosimilar Contract Manufacturing Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
